2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T758,Janus kinase 2 (JAK2) gene fusions characterize cytotoxic cutaneous T-cell lymphoma (CTCL) including primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (pcAETCL). The identification of these fusions is rarely reported in indolent CTCL. To characterize patients with CTCL to better understand the diagnostic, prognostic, and therapeutic significance of this molecular alteration in CTCL. A retrospective case series of patients with CTCL with JAK2 fusions identified between the years 2000 and 2025. Fusions were identified by a custom RNA sequencing panel and by a targeted hybrid-capture-based next-generation DNA sequencing-based panel. The study included a single referral cancer center in the US. Overall, 43 patients (12 female [27.9%] and 31 male individuals [72.1%]; median [range] age, 45 [16-65] years) with CTCL who were found to have JAK2 gene fusions during evaluation and follow-up were included. Thirty-eight of the 43 identified patients (88.4%) with fusions of JAK2 and 10 different gene partners (most frequently ATXN2L, CAPRIN1, and PCM1) had mycosis fungoides (MF), CD30-positive lymphoproliferative disorders (LPD), or overlap presentations, whereas 4 pcAETCL and 1 peripheral T-cell lymphoma not otherwise specified were identified. Secondary genetic events included mutations of epigenetic and transcriptional regulators. Neither mutational burden, type, or fusion partner distinguished cases with early-stage or aggressive CTCL. This case series found that JAK2 fusions were seen in aggressive cytotoxic CTCL as well as in T-cell lymphomas with more indolent behavior, possibly representing a precursor lesion to aggressive evolution with age and comorbidities. The prominence of these fusions supports a potentially larger role for JAK2 targeting in patients with early-stage MF, CD30-positive LPD, or overlap presentations.31:Te18, Importance Janus kinase 2 ( JAK2 ) gene fusions characterize cytotoxic cutaneous T-cell lymphoma (CTCL) including primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (pcAETCL). The identification of these fusions is rarely reported in indolent CTCL. Objective To characterize patients with CTCL to better understand the diagnostic, prognostic, and therapeutic significance of this molecular alteration in CTCL. Design, Setting, and Participants A retrospective case series of patients with CTCL with JAK2 fusions identified between the years 2000 and 2025. Fusions were identified by a custom RNA sequencing panel and by a targeted hybrid-capture-based next-generation DNA sequencing-based panel. The study included a single referral cancer center in the US. Results Overall, 43 patients (12 female [27.9%] and 31 male individuals [72.1%]; median [range] age, 45 [16-65] years) with CTCL who were found to have JAK2 gene fusions during evaluation and follow-up were included. Thirty-eight of the 43 identified patients (88.4%) with fusions of JAK2 and 10 different gene partners (most frequently ATXN2L , CAPRIN1, and PCM1 ) had mycosis fungoides (MF), CD30-positive lymphoproliferative disorders (LPD), or overlap presentations, whereas 4 pcAETCL and 1 peripheral T-cell lymphoma not otherwise specified were identified. Secondary genetic events included mutations of epigenetic and transcriptional regulators. Neither mutational burden, type, or fusion partner distinguished cases with early-stage or aggressive CTCL. Conclusions and Relevance This case series found that JAK2 fusions were seen in aggressive cytotoxic CTCL as well as in T-cell lymphomas with more indolent behavior, possibly representing a precursor lesion to aggressive evolution with age and comorbidities. The prominence of these fusions supports a potentially larger role for JAK2 targeting in patients with early-stage MF, CD30-positive LPD, or overlap presentations. 32:T4ab,This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HCT early in the management of eligible patients with high-risk disease. Advanced stage, large-cell transformation, relapsed or refractory disease following systemic treatment, and N3-stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post-transplant outcomes and survival.33:T4ed,AbstractThis manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo‐HCT) for cutaneous T‐cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post‐transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo‐HCT early in the management of eligible patients with high‐risk disease. Advanced stage, large‐cell transformation, relapsed or refractory disease following systemic treatment, and N3‐stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post‐transplant outcomes and survival.34:T64f,Since the increased use of dupilumab for atopic dermatitis (AD) in daily practice, several cases have been reported on the development of cutaneous T-cell lymphomas (CTCL) and lymphoid infiltrates. To provide insight in the clinical and histopathologic features of patients with AD clinically suspected for CTCL during dupilumab treatment. This retrospective observational case series included adult (≥18 years) patients with AD treated with dupilumab between October 2017 and July 2022 at the University Medical Center Utrecht in the Netherlands. Relevant patient, disease, and treatment characteristics were evaluated. Skin biopsies before, during, and after treatment were collected and reassessed. Fourteen patients (54.5% male) with a median (IQR) age of 56 (36-66) years suspected for CTCL with deterioration of symptoms during dupilumab treatment were included. Of 14 patients, 3 were retrospectively diagnosed with preexistent mycosis fungoides (MF). Eleven patients with AD were eventually diagnosed with a lymphoid reaction (LR). These patients showed MF-like symptoms; however, histopathologic findings were different, and included sprinkled distribution of small hyperchromatic lymphocytes in the upper epidermal section, a dysregulated CD4:CD8 ratio, and CD30 overexpression, without loss of CD2/CD3/CD5. The median time to clinical worsening was 4.0 months (IQR, 1.4-10.0). Posttreatment biopsies showed complete clearance of the LR in all patients. This study found that dupilumab treatment can cause a reversible and benign LR, which mimics a CTCL, though has distinctive histopathologic features.35:T8aa,ImportanceSince the increased use of dupilumab for atopic dermatitis (AD) in daily practice, several cases have been reported on the development of cutaneous T-cell lymphomas (CTCL) and lymphoid infiltrates.ObjectiveTo provide insight in the clinical and histopathologic features of patients with AD clinically suspected for CTCL during dupilumab treatment.Design, Setting, and ParticipantsThis retrospective observational case series included adult (≥18 years) patients with AD treated with dupilumab between October 2017 and July 2022 at the University Medical Center Utrecht in the Netherlands.Main outcomes and measuresRelevant patient, disease, and treatment characteristics were evaluated. Skin biopsies before, during, and after treatment were collected and reassessed.ResultsFourteen patients (54.5% male) with a median (IQR) age of 56 (36-66) years suspected for CTCL with deterioration of symptoms during dupilumab treatment were included. Of 14 patients, 3 were retrospectively diagnosed with preexistent mycosis fungoides (MF). Eleven patients with AD were eventually diagnosed with a lymphoid reaction (LR). These patients showed MF-like symptoms; however, histopathologic findings were different, and included sprinkled distribution of small hyperchromatic lymphocytes in the upper epidermal section, a dysregulated CD4:CD8 ratio, and CD30 overexpression, without loss of CD2/CD3/CD5. The median time to clinical worsening was 4.0 months (IQR, 1.4-10.0). Posttreatment biopsies showed complete clearance of the LR in all patients.Conclusions and relevanceThis study found that dupilumab treatment can cause a reversible and benign LR, which mimics a CTCL, though has distinctive histopathologic features.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Mycosis Fungoides: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Mycosis Fungoides (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Mycosis%20Fungoides\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Mycosis Fungoides\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Mycosis%20Fungoides\"}]}}"}}]],["$","$L2f",null,{"title":"Mycosis Fungoides: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Mycosis Fungoides with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1111/ddg.70555","pmid":"42615429","title":"Infectious risk during mogamulizumab therapy in mycosis fungoides and Sézary syndrome","journal_title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","journal_issn":"1610-0379","published_at":"2026-08-19T00:00:00.000Z","url":"https://doi.org/10.1111/ddg.70555","source_score":3,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-28T06:25:27.223Z","updated_at":"2026-08-28T06:25:27.223Z","tags":[{"paper_doi":"10.1111/ddg.70555","tag_type":"brand","value":"Poteligeo","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"condition","value":"Sézary Syndrome","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"generic","value":"mogamulizumab","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"modality","value":"Anti-CCR4 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"warning","value":"The full text of this paper was not provided — only metadata (title, DOI, journal, publication date). All structured outputs are inferred from the title alone. Numerical results, study design, sample size, age group, sex distribution, and level of evidence could not be extracted or verified. Treat all tags and summaries as provisional pending full-text review.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated the infectious risk associated with mogamulizumab therapy in patients with mycosis fungoides (MF) and Sézary syndrome (SS), a population already prone to immunosuppression-related infections.","limitations":"The full text was not available for review; key numerical outcomes, sample size, study design specifics, and comparator details could not be verified from the provided source data.","practice_takeaway":"Clinicians treating MF/SS with mogamulizumab should maintain heightened vigilance for infectious complications given the drug's immunomodulatory mechanism; prophylactic strategies may warrant consideration."}},{"doi":"10.2340/actadv.v106.adv-2026-0693","pmid":"42516099","title":"Fungal Skin Infections in Cutaneous T-cell Lymphoma Patients under Mogamulizumab Treatment","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0693","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:20.118Z","updated_at":"2026-07-31T13:37:20.118Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"brand","value":"Poteligeo","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Fungal Skin Infection","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Sézary Syndrome","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"amphotericin B","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"ciclopirox","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"fluconazole","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"mogamulizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"terbinafine","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"modality","value":"Anti-CCR4 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"sample_size","value":"n=5","value_numeric":5},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"Causality between mogamulizumab and fungal infections cannot be established from this case series given the heavily pre-treated, immunocompromised patient population.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"The brand name 'Poteligeo' is inferred from mogamulizumab's known proprietary name; it is not explicitly stated in the paper.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"The incidence of 41.7% is from a very small single-center cohort (5/12 patients) and should be interpreted with extreme caution.","value_numeric":null}],"summaries":{"what_studied":"A single-center case series of 5 CTCL patients (1 MF, 4 SS) who developed fungal skin infections during mogamulizumab therapy between January 2021 and December 2024 at a German university center, representing 41.7% (5/12) of all mogamulizumab-treated patients at that institution.","key_result":"5 of 12 mogamulizumab-treated CTCL patients (41.7%) developed fungal skin infections at a mean of 10.6 months after therapy initiation; pathogens included *Candida* spp. (40%), *T. tonsurans* (20%), *T. rubrum* (20%), and *T. interdigitale* (20%). All infections were mild (CTCAE grade 1: 40%; grade 2: 60%); 60% required systemic antifungal therapy (terbinafine or fluconazole) after topical monotherapy failed.","limitations":"- Very small case series (n=5) from a single center; no control group or incidence comparison to other CTCL therapies.\n- Fungal infections may be attributable to the heavily pre-treated, immunocompromised baseline rather than mogamulizumab specifically.\n- Retrospective design with potential for ascertainment bias; infections could be underdiagnosed in the broader mogamulizumab literature.","practice_takeaway":"Clinicians should actively screen CTCL patients on mogamulizumab for fungal skin infections, as these can mimic CTCL lesions or mogamulizumab-associated rash (MAR) and may go undetected. Currently no antifungal prophylaxis guidelines exist for this population; a low threshold for mycological workup (culture, skin scraping, biopsy) is warranted."}},{"doi":"10.2340/actadv.v106.adv-2026-0463","pmid":"42454691","title":"Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-07-15T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0463","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-18T13:39:58.580Z","updated_at":"2026-07-18T13:39:58.580Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"condition","value":"Sézary Syndrome","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"sample_size","value":"n=60","value_numeric":60},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"study_design","value":"Cross-Sectional Observational Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"warning","value":"Stage-related differences (early vs. advanced MF/SS) did not reach statistical significance, likely due to the small advanced-disease subgroup (n=12); trends should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"warning","value":"The psoriasis comparator cohort (GÖTHA) was collected separately and may differ in data collection period and context, which could introduce unmeasured confounding.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"warning","value":"Treatment data were not collected for the MF/SS cohort, so the influence of active therapies on symptom burden and psychological outcomes cannot be assessed.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"warning","value":"VAS fatigue comparison between MF/SS and psoriasis did not reach significance (p=0.49) despite a numerically higher median in MF/SS, which may reflect insufficient power.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional questionnaire study assessed psychological distress (MADRS-S, HADS), symptom burden (VAS for pruritus, pain, fatigue), and quality of life (DLQI) in 60 patients with mycosis fungoides (MF) or Sézary syndrome (SS) in Western Sweden (80% early-stage), and compared outcomes with 139 psoriasis patients.","key_result":"Most MF/SS patients reported minimal depression, anxiety, and QoL impairment; however, moderate-to-severe depression occurred in 36% of advanced vs. 16% of early-stage patients, and moderate-to-severe QoL impairment (DLQI ≥6) in 33% vs. 17%, respectively. Fatigue was the dominant symptom (median VAS 3) and correlated strongly with depression (MADRS-S ρ=0.60, HADS-D ρ=0.63), anxiety (ρ=0.49), and impaired QoL (ρ=0.53; all p<0.001). Pruritus strongly predicted QoL impairment (ρ=0.67, p<0.001). Compared to psoriasis, MF/SS patients had lower DLQI (median 1 vs. 3, p=0.001) and lower pain scores (median VAS 0 vs. 0.8, p<0.001), but similar fatigue.","limitations":"- Small sample with only 12 advanced-stage patients severely limits statistical power to detect stage-related differences.\n- Cross-sectional design at a single time point across varied disease phases and treatments; treatment data were not collected.\n- Disease severity was not quantified with validated tools (e.g., mSWAT), preventing correlation of skin burden with patient-reported outcomes.","practice_takeaway":"Routinely screen MF/SS patients — especially those with advanced disease — for fatigue and depression, as both are under-recognized drivers of QoL impairment beyond what skin severity scores capture. Pruritus control should remain a priority given its strong independent association with reduced QoL."}},{"doi":"10.1097/pas.0000000000002572","pmid":"42210690","title":"TRBC1 Immunohistochemistry Utilization in Formalin-fixed Paraffin-embedded Tissue as an Adjunct to T-cell Clonality Testing in the Assessment of Cutaneous Lymphoproliferative Disorders","journal_title":"American Journal of Surgical Pathology","journal_issn":"0147-5185","published_at":"2026-05-29T00:00:00.000Z","url":"https://doi.org/10.1097/pas.0000000000002572","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-05T13:26:47.139Z","updated_at":"2026-06-05T13:26:47.139Z","tags":[{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"condition","value":"Cutaneous Lymphoproliferative Disorder","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"generic","value":"TRBC1","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"modality","value":"Immunohistochemistry","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"sample_size","value":"n=67","value_numeric":67},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"warning","value":"Sample size of 67 total (36 cases + 31 controls) is small; subgroup analyses (MF vs. non-MF, intraepithelial vs. full infiltrate) are based on even smaller subsets, increasing uncertainty around reported sensitivities.","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"warning","value":"The full text body was not accessible in the provided content (only publisher permission guidelines were returned); all extracted data are derived exclusively from the abstract.","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"warning","value":"TRBC1 is referenced as a nonproprietary target/marker rather than a conventional drug; it has been tagged under 'generic' for discoverability but is a diagnostic antibody, not a therapeutic agent.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated TRBC1 immunohistochemistry (IHC) in FFPE skin biopsies as an adjunct marker for T-cell clonality across 36 cases of cutaneous T-cell lymphoproliferative disorders (including mycosis fungoides and non-MF CTCL) and 31 polyclonal controls, comparing results to molecular clonality testing.","key_result":"Overall concordance of TRBC1 IHC with molecular clonality testing was 79% (sensitivity 64%, specificity 97%, PPV 96%, NPV 70%); sensitivity improved to 72% in MF cases but dropped to 50% when restricted to intraepithelial T-cells only, and to 56% in non-MF CTCL. Optimal discrimination used thresholds of ≤20% or ≥80% (or ≤30%/≥70%) TRBC1-positive cells among CD3+ T-cells.","limitations":"- Modest sample size (36 cases, 31 controls) limits generalizability.\n- TRBC1 IHC cannot detect clonality in TCR-γ/δ T-cell disorders (no β-chain expression), limiting applicability to a subset of CTCLs.\n- Sensitivity for intraepithelial lymphocytes is notably low (50%), restricting utility in assessment strategies focused on that compartment.","practice_takeaway":"TRBC1 IHC on FFPE skin biopsies is a useful adjunct for clonality assessment in mycosis fungoides—especially when evaluating the full dermal infiltrate rather than intraepithelial cells alone—but should not replace molecular clonality testing given its limited sensitivity. It offers no signal in TCR-γ/δ lymphomas, so confirm T-cell receptor subtype before applying this marker."}},{"doi":"10.2340/actadv.v106.adv-2026-0467","pmid":"42112782","title":"Purplish-brown Patches and Ecchymoses on the Dorsal Hands: A Quiz","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-05-11T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0467","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-14T13:23:03.729Z","updated_at":"2026-05-14T13:23:03.729Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"condition","value":"Pigmented Purpura Dermatosis-Like Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"generic","value":"topical glucocorticoid","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"modality","value":"Phototherapy","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"warning","value":"Study design is ambiguous between a 'quiz/case report' and a clinical case series format; tagged as Case Report based on content.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"warning","value":"TCR gene rearrangement was not performed; diagnosis rests on clinicopathological correlation alone, which may limit diagnostic certainty.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"warning","value":"This is a single case report — findings, particularly regarding the CD8-predominant phenotype in PPD-like MF, cannot be generalized.","value_numeric":null}],"summaries":{"what_studied":"A 24-year-old man with a 3-year history of purplish-brown patches and ecchymoses isolated to the dorsal hands was evaluated to reach a diagnosis via two-site biopsy and immunohistochemistry, with a 1-year treatment follow-up using phototherapy and topical glucocorticoids.","key_result":"Diagnosis of pigmented purpura dermatosis-like mycosis fungoides (PPD-like MF) was confirmed by histopathology showing epidermotropism of atypical lymphocytes, Pautrier microabscesses, and a CD8-predominant (CD7 partial loss) immunophenotype — features distinguishing it from lichen aureus and Woringer–Kolopp disease. After 1 year of treatment, only partial improvement was observed.","limitations":"- Single case report; no T-cell receptor (TCR) gene rearrangement was performed, which would have strengthened the diagnosis.\n- Long-term outcomes and whether CD8-predominant immunophenotype confers a more favorable prognosis in PPD-like MF (as it does in hypopigmented MF) remain unknown.","practice_takeaway":"Consider PPD-like MF in persistent purpuric or pigmented hand lesions lasting >1 year that respond poorly to standard pigmented purpuric dermatosis therapy — two-site biopsy with immunohistochemistry (including CD7, CD8, CD30) is key to distinguishing it from benign mimics. A CD8-predominant T-cell phenotype is unusual for classic MF and should prompt careful clinicopathological correlation."}},{"doi":"10.1001/jamadermatol.2025.4688","pmid":"41296329","title":"JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-11-26T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.4688","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-11-27","doi":"10.1001/jamadermatol.2025.4688","days":"7","issn":"2168-6068","rank":"8","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.4688","title":"JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders.","journal":"JAMA dermatology","methods":"","results":"Overall, 43 patients (12 female [27.9%] and 31 male individuals [72.1%]; median [range] age, 45 [16-65] years) with CTCL who were found to have JAK2 gene fusions during evaluation and follow-up were included. Thirty-eight of the 43 identified patients (88.4%) with fusions of JAK2 and 10 different gene partners (most frequently ATXN2L, CAPRIN1, and PCM1) had mycosis fungoides (MF), CD30-positive lymphoproliferative disorders (LPD), or overlap presentations, whereas 4 pcAETCL and 1 peripheral T-cell lymphoma not otherwise specified were identified. Secondary genetic events included mutations of epigenetic and transcriptional regulators. Neither mutational burden, type, or fusion partner distinguished cases with early-stage or aggressive CTCL.","abstract":"$30","keywords":[],"pubmed_id":"41296329","conclusions":"","publication_date":"2025-11-26T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.4688","URL":"https://doi.org/10.1001/jamadermatol.2025.4688","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2841751/jamadermatology_geller_2025_oi_250057_1763325626.56939.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders"],"author":[{"given":"Shamir","family":"Geller","sequence":"first","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Dermatology, Weill Cornell Medicine, New York, New York"}]},{"given":"Viviane","family":"Liao","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Leore","family":"Lavin","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}]},{"given":"Haiming","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Mia","family":"Do","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Andrea","family":"Moy","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Cesar A.","family":"Virgen","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Liam","family":"Donnelly","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Melissa P.","family":"Pulitzer","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York"}]}],"issued":{"date-parts":[[2025,11,26]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-11-26T16:31:37Z","timestamp":1764174697000,"date-parts":[[2025,11,26]]},"indexed":{"date-time":"2025-11-26T16:36:34Z","timestamp":1764174994921,"date-parts":[[2025,11,26]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2841751"}},"subtitle":[],"deposited":{"date-time":"2025-11-26T16:31:38Z","timestamp":1764174698000,"date-parts":[[2025,11,26]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,11,26]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1182/blood.2022016690","key":"doi250057r1","year":"2023","issue":"2","author":"Gluud","volume":"141","first-page":"180","unstructured":null,"article-title":"Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.3324/haematol.2020.274506","key":"doi250057r2","year":"2022","issue":"3","author":"Bastidas Torres","volume":"107","first-page":"702","unstructured":null,"article-title":"Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma.","journal-title":"Haematologica","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2021012536","key":"doi250057r3","year":"2021","issue":"23","author":"Lee","volume":"138","first-page":"2435","unstructured":null,"article-title":"Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00428-022-03372-x","key":"doi250057r4","year":"2022","issue":"6","author":"Rodriguez-Sevilla","volume":"481","first-page":"967","unstructured":null,"article-title":"PCM1:JAK2 fusion associates with an atypical form of mycosis fungoides.","journal-title":"Virchows Arch","doi-asserted-by":"publisher"},{"DOI":"10.18632/oncotarget.21790","key":"doi250057r5","year":"2017","issue":"61","author":"Panagopoulos","volume":"8","first-page":"103775","unstructured":null,"article-title":"Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.","journal-title":"Oncotarget","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2018-01-830968","key":"doi250057r6","year":"2018","issue":"20","author":"Sharma","volume":"131","first-page":"2262","unstructured":null,"article-title":"Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.xjidi.2021.100034","key":"doi250057r7","year":"2021","issue":"3","author":"Wobser","volume":"1","first-page":null,"unstructured":null,"article-title":"Oncogenic mutations and gene fusions in CD30-positive lymphoproliferations and clonally related mycosis fungoides occurring in the same patients.","journal-title":"JID Innov","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2020.02.019","key":"doi250057r8","year":"2020","issue":"10","author":"Maurus","volume":"140","first-page":"2023","unstructured":null,"article-title":"Recurrent oncogenic JAK and STAT alterations in cutaneous CD30-positive lymphoproliferative disorders.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1097/PAS.0000000000001708","key":"doi250057r9","year":"2021","issue":"7","author":"Fitzpatrick","volume":"45","first-page":"895","unstructured":null,"article-title":"JAK2 rearrangements are a recurrent alteration in CD30+ systemic t-cell lymphomas with anaplastic morphology.","journal-title":"Am J Surg Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1111/tbj.14205","key":"doi250057r10","year":"2021","issue":"4","author":"Quesada","volume":"27","first-page":"314","unstructured":null,"article-title":"Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway.","journal-title":"Breast J","doi-asserted-by":"publisher"},{"DOI":"10.1128/MCB.20.10.3387-3395.2000","key":"doi250057r11","year":"2000","issue":"10","author":"Saharinen","volume":"20","first-page":"3387","unstructured":null,"article-title":"Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.","journal-title":"Mol Cell Biol","doi-asserted-by":"publisher"},{"DOI":"10.1038/nsmb.2099","key":"doi250057r12","year":"2011","issue":"9","author":"Ungureanu","volume":"18","first-page":"971","unstructured":null,"article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.","journal-title":"Nat Struct Mol Biol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":12,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,26]]},"references-count":12,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.4688","is_oa":false,"title":"JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders","updated":"2025-11-27T02:22:14+00:00","published_date":"2025-11-26","best_oa_location":null}},"created_at":"2025-11-30T07:03:02.464Z","updated_at":"2025-12-02T07:03:10.886Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"condition","value":"CD30-Positive Lymphoproliferative Disorder","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"condition","value":"Primary Cutaneous Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"sample_size","value":"n=43","value_numeric":43},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"warning","value":"The abstract does not report treatment response or survival outcomes.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"warning","value":"Title specifies adults, but the reported age range includes a 16-year-old.","value_numeric":null}],"summaries":{"what_studied":"A retrospective case series from a single US referral cancer center (2000–2025) describing cutaneous T-cell lymphoma (CTCL) patients with JAK2 fusions detected by custom RNA sequencing and targeted DNA panels. The study characterized diagnostic, prognostic, and therapeutic context of these fusions.","key_result":"Among 43 patients (12 female, 31 male; median age 45 [16–65]), 38/43 (88.4%) with JAK2 fusions had mycosis fungoides, CD30‑positive lymphoproliferative disorders, or overlap; 4 had pcAETCL and 1 had PTCL‑NOS. Ten fusion partners were identified (most often ATXN2L, CAPRIN1, PCM1); secondary events involved epigenetic/transcriptional regulators, and fusion partner, type, or mutational burden did not distinguish early‑stage from aggressive CTCL.","limitations":"Retrospective, single‑center case series. Detection relied on custom sequencing panels, which may limit generalizability.","practice_takeaway":"JAK2 fusions are present across the CTCL spectrum, including MF and CD30‑positive LPD, not just in aggressive cytotoxic variants. In this cohort, fusion partner, type, and burden did not stratify early vs aggressive disease, so the fusion profile alone should not guide risk assessment."}},{"doi":"10.1111/jdv.70042","pmid":"41031482","title":"Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee","journal_title":"Journal of the European Academy of Dermatology and Venereology","journal_issn":"0926-9959","published_at":"2025-10-01T00:00:00.000Z","url":"https://doi.org/10.1111/jdv.70042","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-05","doi":"10.1111/jdv.70042","days":"7","issn":"0926-9959","rank":"10","field":"Clinical Medicine","score":"1","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jdv.70042","title":"Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","methods":"","results":"","abstract":"$32","keywords":["Sézary syndrome","allogeneic transplantation","cutaneous T‐cell","lymphomas","mycosis fungoides","skin cancer"],"pubmed_id":"41031482","conclusions":"","publication_date":"2025-10-01T00:00:00"},"crossref":{"DOI":"10.1111/jdv.70042","URL":"https://doi.org/10.1111/jdv.70042","ISSN":["0926-9959","1468-3083"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.70042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee"],"author":[{"given":"Gandhi","family":"Damaj","sequence":"first","affiliation":[{"name":"Caen University Hospital Hematology Institute, Normandy University, School of Medicine Caen France"}]},{"given":"Adèle","family":"de Masson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Saint‐Louis Hospital, AP‐HP, National Reference Center for Cutaneous Lymphomas, Institut du Cancer AP‐HP Nord, Université Paris Cité Paris France"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"Department of Medicine V University of Heidelberg Heidelberg Germany"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Chair of the EBMT Lymphoma Working Party, Bone Marrow Transplantation Program, Department of Internal Medicine American University of Beirut Beirut Lebanon"}]},{"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]},{"given":"Rafael F.","family":"Duarte","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain"}]},{"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham Nottingham UK"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[{"name":"University Institute and Clinic for Immuno‐Dermatology, Medical Faculty Johannes Kepler University, Secretary of the EORTC Cutaneous Lymphoma Tumor Group Linz Austria"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Service d'Hématologie Adultes, Institut Necker Enfants Malades, Unité INSERM U1153, Hôpital Universitaire Necker‐Enfants Malades, AP‐HP, Université Paris Cité and Imagine Institute Paris France"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[{"name":"Secretary of the EBMT LWP, Department of Hematology University College London Hospital London UK"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute University of Medicine and Pharmacy Carol Davila Bucharest Romania"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy Clermont‐Ferrand University Hospital, UCA, EA7453 Chelter CIC‐1405 Clermont‐Ferrand France"}]},{"given":"Wojiech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Maria Sklodowska Curie National Research Institute of Oncology Krakow Poland"}]},{"given":"Imke E.","family":"Karsten","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]},{"given":"Stéphanie Nguyen","family":"Quoc","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cellular Therapies Sorbonne University Pitié‐Salpêtrière Hospital Paris France"}]},{"given":"Yasmina","family":"Serroukh","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC Cancer Institute, University Medical Center Rotterdam Rotterdam The Netherlands"}]},{"given":"Federico","family":"Stella","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale Dei Tumori Milano, University of Milano Milan Italy"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Hospital Goettingen Goettingen Germany"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Institut Català d'Oncologia – L'hospitalet, Institut de Recerca Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Barcelona Spain"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[{"name":"Department of Dermatology National and Kapodistrian University of Athens, Attikon University Hospital Athens Greece"}]},{"given":"Pablo L.","family":"Ortiz‐Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology Institute i+12, Hospital 12 de Octubre Medical School University Complutense Madrid Spain"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Co‐Chair of the Practice Harmonisation and Guidelines Committee of EBMT and Chair of the CTIWP of the EBMT. Hematology and BMT Unit IRCCS San Raffaele Hospital Milan Italy"}]},{"given":"Isabel","family":"Sánchez‐Ortega","sequence":"additional","affiliation":[{"name":"Secretary of the Practice Harmonisation and Guidelines Committee of EBMT; EBMT Medical Officer, Executive Office Barcelona Spain"}]},{"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"University Hospital Birmingham and University of Birmingham Birmingham UK"}]},{"given":"Ibrahim","family":"Yakoub‐Agha","sequence":"additional","affiliation":[{"name":"Chair of the EBMT Practice Harmonisation and Guidelines Committee; Lille University Hospital, Lille University, INSERM U1286, Infinite Lille France"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"Co‐Chair of the Practice Harmonisation and Guidelines Committee of the EBMT; Hematology and BMT Centre, ASST Fatebenefratelli‐Sacco University of Milan Milan Italy"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-01T10:01:09Z","timestamp":1759312869000,"date-parts":[[2025,10,1]]},"indexed":{"date-time":"2025-10-02T00:41:49Z","timestamp":1759365709081,"date-parts":[[2025,10,2]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000,"date-parts":[[2025,10,1]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.70042"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-04-10"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-07-11"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-01"}],"deposited":{"date-time":"2025-10-01T10:01:10Z","timestamp":1759312870000,"date-parts":[[2025,10,1]]},"issn-type":[{"type":"print","value":"0926-9959"},{"type":"electronic","value":"1468-3083"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/bjd.19644","key":"e_1_2_15_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers12102921","key":"e_1_2_15_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2018-11-881268","key":"e_1_2_15_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17258","key":"e_1_2_15_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.10.006","key":"e_1_2_15_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2011.39.8065","key":"e_1_2_15_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdt480","key":"e_1_2_15_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.21449","key":"e_1_2_15_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00277-014-2121-1","key":"e_1_2_15_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(18)30379-6","key":"e_1_2_15_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)31266-7","key":"e_1_2_15_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2015.61.7142","key":"e_1_2_15_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18541","key":"e_1_2_15_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00329-X","key":"e_1_2_15_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-020-01197-3","key":"e_1_2_15_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2010.29.3241","key":"e_1_2_15_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2019.08.019","key":"e_1_2_15_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/14737140.2024.2305356","key":"e_1_2_15_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2023.113343","key":"e_1_2_15_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtct.2024.08.020","key":"e_1_2_15_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-023-01958-w","key":"e_1_2_15_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2021012057","key":"e_1_2_15_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.10.014","key":"e_1_2_15_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2010.28.9066","key":"e_1_2_15_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2014.57.5597","key":"e_1_2_15_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2024.102679","key":"e_1_2_15_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s12185-024-03753-9","key":"e_1_2_15_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2016.67.8250","key":"e_1_2_15_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2007-03-055749","key":"e_1_2_15_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2009.27.7665","key":"e_1_2_15_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/PAT.0000000000000166","key":"e_1_2_15_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2013.09.007","key":"e_1_2_15_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clml.2017.11.004","key":"e_1_2_15_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2020.1790555","key":"e_1_2_15_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-2950","key":"e_1_2_15_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/bloodadvances.2020001627","key":"e_1_2_15_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-024-02236-z","key":"e_1_2_15_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.3007420","key":"e_1_2_15_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18806","key":"e_1_2_15_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18215","key":"e_1_2_15_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19220","key":"e_1_2_15_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2009.25.8301","key":"e_1_2_15_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2024.11.011","key":"e_1_2_15_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2019.1658106","key":"e_1_2_15_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-023-02122-0","key":"e_1_2_15_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_47_1","year":"2024","issue":null,"author":"Onida F","volume":"59","first-page":null,"unstructured":null,"article-title":"Allogeneic hematopoietic cell transplantation in patients with advanced mycosis fungoides and Sézary syndrome: a retrospective analysis including 63 consecutive patients with long‐term median follow‐up","journal-title":"Bone Marrow Transplant","doi-asserted-by":null},{"DOI":"10.1182/bloodadvances.2021005899","key":"e_1_2_15_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtct.2022.11.028","key":"e_1_2_15_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2018.06.026","key":"e_1_2_15_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2006.08.0952","key":"e_1_2_15_51_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.02408","key":"e_1_2_15_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2991/chi.k.210529.001","key":"e_1_2_15_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/ajh.27531","key":"e_1_2_15_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/09636897241270401","key":"e_1_2_15_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2024.2376164","key":"e_1_2_15_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-018-0400-5","key":"e_1_2_15_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2352-3026(19)30256-X","key":"e_1_2_15_58_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.15661","key":"e_1_2_15_59_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clml.2020.06.020","key":"e_1_2_15_60_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00508-4","key":"e_1_2_15_61_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jdv.70042"],"article-number":"jdv.70042","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"reference-count":60,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10]]},"references-count":60,"short-container-title":["Acad Dermatol Venereol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jdv.70042","is_oa":true,"title":"Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee","updated":"2025-10-06T00:09:52+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.70042","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.70042","url_for_landing_page":"https://doi.org/10.1111/jdv.70042"}}},"created_at":"2025-10-10T09:56:52.931Z","updated_at":"2025-10-10T09:56:52.931Z","tags":[{"paper_doi":"10.1111/jdv.70042","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Sezary Syndrome","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"study_design","value":"Guideline","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"Recommendations against routine MRD monitoring or maintenance reflect insufficient evidence, not proof of no benefit.","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"Some donor-source comparisons (especially haploidentical) derive from small cohorts and may not generalize.","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"This is a consensus guideline synthesizing heterogeneous studies rather than a single trial.","value_numeric":null}],"summaries":{"what_studied":"Expert consensus guidance from the EBMT PH&G Committee on when and how to use allogeneic haematopoietic cell transplantation for cutaneous T‑cell lymphomas (mycosis fungoides and Sézary syndrome), covering referral criteria, timing/bridging, donor selection, conditioning/GVHD prophylaxis, and post‑transplant care.","key_result":"In the CUTALLO propensity‑matched prospective study (n=99), allo‑HCT prolonged PFS to 9.0 months vs 3.0 months with conventional therapy (HR 0.38, 95% CI 0.21–0.69; p<0.0001). Historical/pooled benchmarks for allo‑HCT show 5‑year OS 38% and PFS 26% (EBMT registry), and OS 51% at 1 year and 40% at 3 years with PFS 42% at 1 year and 33% at 3 years (meta‑analysis).","limitations":"Recommendations rest largely on retrospective series, registry analyses, and small prospective cohorts, with heterogeneous conditioning, donor sources, and peri‑transplant practices. Evidence for haploidentical donors, modern GVHD prophylaxis (e.g., PTCy), MRD monitoring, and maintenance strategies remains limited or inconclusive.","practice_takeaway":"Refer high‑risk MF/SS early; aim for CR or deep response (VGPR or mSWAT <10) before RIC allo‑HCT, prefer MRD/MUD donors, and observe a 6‑week washout after pre‑HCT mogamulizumab. Manage relapse with immunosuppression taper and DLI, adding site‑directed therapy or TSEB as indicated; routine post‑HCT MRD monitoring or maintenance is not recommended."}},{"doi":"10.1093/bjd/ljaf233","pmid":"40577522","title":"Increased mortality due to lymphoma and infections in patients with mycosis fungoides or Sézary syndrome: a Swedish nationwide population-based cohort study","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2025-06-27T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljaf233","source_score":62,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-07-11","doi":"10.1093/bjd/ljaf233","days":"30","issn":"0007-0963","rank":"5","field":"Clinical Medicine","score":"62","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1093/bjd/ljaf233","title":"Increased mortality due to lymphoma and infections in patients with mycosis fungoides or Sézary syndrome: A Swedish nationwide, population-based cohort study.","journal":"The British journal of dermatology","methods":"","results":"","abstract":"","keywords":[],"pubmed_id":"40577522","conclusions":"","publication_date":"2025-06-27T00:00:00"},"crossref":{"DOI":"10.1093/bjd/ljaf233","URL":"https://doi.org/10.1093/bjd/ljaf233","ISSN":["0007-0963","1365-2133"],"link":[{"URL":"https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljaf233/63523895/ljaf233.pdf","content-type":"application/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljaf233/63523895/ljaf233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Increased mortality due to lymphoma and infections in patients with mycosis fungoides or Sézary syndrome: a Swedish nationwide population-based cohort study"],"author":[{"given":"Lina U","family":"Ivert","sequence":"first","affiliation":[{"name":"Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet , Stockholm ,"},{"name":"Department of Dermatology, Karolinska University Hospital , Stockholm ,"}]},{"given":"Sara","family":"Ekberg","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet , Stockholm ,"},{"name":"Red Door Analytics AB , Stockholm ,"}]},{"given":"Karin E","family":"Smedby","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet , Stockholm ,"},{"name":"Department of Hematology, Karolinska University Hospital , Stockholm ,"}]},{"given":"Hanna","family":"Brauner","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet , Stockholm ,"},{"name":"Department of Dermatology, Karolinska University Hospital , Stockholm ,"},{"name":"Center for Molecular Medicine, Karolinska Institutet , Stockholm ,"}]}],"funder":[{"id":[{"id":"10.13039/501100003748","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100003748","name":"Swedish Society for Medical Research","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100012538","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100012538","name":"Swedish Cancer Foundation","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/501100004047","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2025,6,19]]},"member":"286","prefix":"10.1093","source":"Crossref","volume":null,"created":{"date-time":"2025-06-27T14:05:53Z","timestamp":1751033153000,"date-parts":[[2025,6,27]]},"indexed":{"date-time":"2025-08-02T14:31:29Z","timestamp":1754145089482,"date-parts":[[2025,8,2]]},"license":[{"URL":"https://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000,"date-parts":[[2025,6,19]]},"delay-in-days":0,"content-version":"am"}],"subject":[],"abstract":"This large population-based study confirms lymphoma as the leading cause of death in patients with mycosis fungoides/Sézary syndrome (MF/SS), particularly those with severe disease. Patients with MF/SS also had higher mortality from infections, although the absolute infection-related mortality was low. Mortality from other explored causes was not elevated compared with the general population. Patients with mild MF/SS had significantly better outcomes, highlighting the heterogeneity of the disease.","language":"en","relation":{},"resource":{"primary":{"URL":"https://academic.oup.com/bjd/advance-article/doi/10.1093/bjd/ljaf233/8168906"}},"subtitle":[],"deposited":{"date-time":"2025-07-16T14:31:51Z","timestamp":1752676311000,"date-parts":[[2025,7,16]]},"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"published":{"date-parts":[[2025,6,19]]},"publisher":"Oxford University Press (OUP)","reference":[{"DOI":"10.1038/s41572-021-00296-9","key":"2025071610314080900_ljaf233-B1","year":"2021","issue":null,"author":"Dummer","volume":"7","first-page":"61","unstructured":null,"article-title":"Cutaneous T cell lymphoma","journal-title":"Nat Rev Dis Primers","doi-asserted-by":"crossref"},{"DOI":"10.1007/s10654-017-0316-1","key":"2025071610314080900_ljaf233-B2","year":"2017","issue":null,"author":"Brooke","volume":"32","first-page":"765","unstructured":null,"article-title":"The Swedish cause of death register","journal-title":"Eur J Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1111/bcpt.12613","key":"2025071610314080900_ljaf233-B3","year":"2016","issue":null,"author":"Wallerstedt","volume":"119","first-page":"464","unstructured":null,"article-title":"The first decade with the Swedish prescribed drug register – a systematic review of the output in the scientific literature","journal-title":"Basic Clin Pharmacol Toxicol","doi-asserted-by":"crossref"},{"DOI":"10.2147/CLEP.S282475","key":"2025071610314080900_ljaf233-B4","year":"2021","issue":null,"author":"Ludvigsson","volume":"13","first-page":"21","unstructured":null,"article-title":"Adaptation of the Charlson Comorbidity Index for register-based research in Sweden","journal-title":"Clin Epidemiol","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.26760","key":"2025071610314080900_ljaf233-B5","year":"2023","issue":null,"author":"Hristov","volume":"98","first-page":"193","unstructured":null,"article-title":"Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.lpm.2022.104123","key":"2025071610314080900_ljaf233-B6","year":"2022","issue":null,"author":"Scarisbrick","volume":"51","first-page":"104123","unstructured":null,"article-title":"The PROCLIPI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas","journal-title":"Presse Med","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.17194","key":"2025071610314080900_ljaf233-B7","year":"2018","issue":null,"author":"Scarisbrick","volume":"179","first-page":"1243","unstructured":null,"article-title":"Infections in mycosis fungoides and Sézary syndrome are a frequent cause of morbidity and contribute to mortality. What can be done?","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2018888107","key":"2025071610314080900_ljaf233-B8","year":"2019","issue":null,"author":"Lindahl","volume":"134","first-page":"1072","unstructured":null,"article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"}],"short-title":[],"article-number":"ljaf233","content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["British Journal of Dermatology"],"reference-count":8,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,6,19]]},"references-count":8,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1093/bjd/ljaf233","is_oa":true,"title":"Increased mortality due to lymphoma and infections in patients with mycosis fungoides or Sézary syndrome: a Swedish nationwide population-based cohort study","updated":"2025-09-06T02:51:56+00:00","published_date":"2025-06-19","best_oa_location":{"url":"https://doi.org/10.1093/bjd/ljaf233","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1093/bjd/ljaf233"}}},"created_at":"2025-09-19T18:26:15.728Z","updated_at":"2025-09-19T18:32:12.839Z","tags":[{"paper_doi":"10.1093/bjd/ljaf233","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljaf233","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1093/bjd/ljaf233","tag_type":"condition","value":"Sézary Syndrome","value_numeric":null},{"paper_doi":"10.1093/bjd/ljaf233","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/bjd/ljaf233","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1093/bjd/ljaf233","tag_type":"warning","value":"Only title and citation details were available; no numeric outcomes, sample size, or effect estimates were provided.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljaf233","tag_type":"warning","value":"Timeframe, comparator group, and absolute risks are not specified in the provided text.","value_numeric":null}],"summaries":{"what_studied":"A nationwide population-based cohort in Sweden assessed cause-specific mortality from lymphoma and infections among people with mycosis fungoides or Sézary syndrome."}},{"doi":"10.1001/jamadermatol.2023.3849","pmid":"37851456","title":"Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2023-10-18T00:00:00.000Z","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10585590","source_score":54,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2023-11-15","doi":"10.1001/jamadermatol.2023.3849","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"54","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2023.3849","title":"Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis.","journal":"JAMA dermatology","methods":"","results":"Fourteen patients (54.5% male) with a median (IQR) age of 56 (36-66) years suspected for CTCL with deterioration of symptoms during dupilumab treatment were included. Of 14 patients, 3 were retrospectively diagnosed with preexistent mycosis fungoides (MF). Eleven patients with AD were eventually diagnosed with a lymphoid reaction (LR). These patients showed MF-like symptoms; however, histopathologic findings were different, and included sprinkled distribution of small hyperchromatic lymphocytes in the upper epidermal section, a dysregulated CD4:CD8 ratio, and CD30 overexpression, without loss of CD2/CD3/CD5. The median time to clinical worsening was 4.0 months (IQR, 1.4-10.0). Posttreatment biopsies showed complete clearance of the LR in all patients.","abstract":"$34","keywords":[],"pubmed_id":"37851456","conclusions":"","publication_date":"2023-10-18T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2023.3849","URL":"https://doi.org/10.1001/jamadermatol.2023.3849","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2810836/jamadermatology_boesjes_2023_oi_230050_1699989182.38982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"1240","type":"journal-article","issue":"11","score":1,"title":["Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis"],"author":[{"given":"Celeste M.","family":"Boesjes","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands"}]},{"given":"Lian F.","family":"van der Gang","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands"}]},{"given":"Daphne S.","family":"Bakker","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands"}]},{"given":"Tess A.","family":"ten Cate","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands"}]},{"given":"Lotte S.","family":"Spekhorst","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands"}]},{"given":"Marlies","family":"de Graaf","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands"}]},{"given":"Marijke R.","family":"van Dijk","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands"}]},{"given":"Marjolein S.","family":"de Bruin-Weller","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands"}]}],"issued":{"date-parts":[[2023,11,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"159","created":{"date-time":"2023-10-18T15:02:43Z","timestamp":1697641363000,"date-parts":[[2023,10,18]]},"indexed":{"date-time":"2025-09-20T17:24:36Z","timestamp":1758389076293,"date-parts":[[2025,9,20]]},"subject":[],"abstract":"$35","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2810836"}},"subtitle":[],"deposited":{"date-time":"2023-11-15T16:02:33Z","timestamp":1700064153000,"date-parts":[[2023,11,15]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2023,11,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/S0140-6736(15)00149-X","key":"doi230050r1","year":"2016","issue":"10023","author":"Weidinger","volume":"387","first-page":"1109","unstructured":null,"article-title":"Atopic dermatitis.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.08.127","key":"doi230050r2","year":"2021","issue":"4","author":"Ariëns","volume":"84","first-page":"1000","unstructured":null,"article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2020.03.050","key":"doi230050r3","year":"2020","issue":"1","author":"Espinosa","volume":"83","first-page":"197","unstructured":null,"article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1097/DAD.0000000000001875","key":"doi230050r4","year":"2021","issue":"10","author":"Sokumbi","volume":"43","first-page":"714","unstructured":null,"article-title":"Evolution of dupilumab-associated cutaneous atypical lymphoid infiltrates.","journal-title":"Am J Dermatopathol","doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v102.2234","key":"doi230050r5","year":"2022","issue":null,"author":"Hashimoto","volume":"102","first-page":null,"unstructured":null,"article-title":"Development of nodular lesions after dupilumab therapy in erythrodermic mycosis fungoides with interleukin-13 receptor alpha2 expression.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1590/abd1806-4841.20187106","key":"doi230050r6","year":"2018","issue":"4","author":"Amorim","volume":"93","first-page":"546","unstructured":null,"article-title":"Clinical and epidemiological profile of patients with early stage mycosis fungoides.","journal-title":"An Bras Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3367","key":"doi230050r7","year":"2020","issue":"1","author":"Maguire","volume":"100","first-page":null,"unstructured":null,"article-title":"Early-stage Mycosis Fungoides: Epidemiology and Prognosis.","journal-title":"Acta Derm Venereol","doi-asserted-by":"publisher"},{"DOI":"10.3390/ijms222413388","key":"doi230050r8","year":"2021","issue":"24","author":"Kolkowski","volume":"22","first-page":"13388","unstructured":null,"article-title":"Safety and Danger Considerations of Novel Treatments for Atopic Dermatitis in Context of Primary Cutaneous Lymphomas.","journal-title":"Int J Mol Sci","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2015.02.1116","key":"doi230050r9","year":"2015","issue":"6","author":"Legendre","volume":"72","first-page":"992","unstructured":null,"article-title":"Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.1948","key":"doi230050r10","year":"2020","issue":"10","author":"Mansfield","volume":"156","first-page":"1086","unstructured":null,"article-title":"Association Between Atopic Eczema and Cancer in England and Denmark.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2014-07-590398","key":"doi230050r11","year":"2015","issue":"18","author":"Geskin","volume":"125","first-page":"2798","unstructured":null,"article-title":"Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1155/2016/9717530","key":"doi230050r12","year":"2016","issue":null,"author":"Saulite","volume":"2016","first-page":null,"unstructured":null,"article-title":"Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets.","journal-title":"Biomed Res Int","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2018-11-881268","key":"doi230050r14","year":"2019","issue":"16","author":"Willemze","volume":"133","first-page":"1703","unstructured":null,"article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.semdp.2009.09.001","key":"doi230050r15","year":"2009","issue":"3","author":"Guitart","volume":"26","first-page":"131","unstructured":null,"article-title":"Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue.","journal-title":"Semin Diagn Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.semdp.2016.11.005","key":"doi230050r16","year":"2017","issue":"1","author":"Kempf","volume":"34","first-page":"22","unstructured":null,"article-title":"A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.","journal-title":"Semin Diagn Pathol","doi-asserted-by":"publisher"},{"DOI":"10.12788/cutis","key":"doi230050r17","year":"2020","issue":"2","author":"Hollins","volume":"106","first-page":"E8","unstructured":null,"article-title":"Long-standing dermatitis treated with dupilumab with subsequent progression to cutaneous T-cell lymphoma.","journal-title":"Cutis","doi-asserted-by":"publisher"},{"DOI":"10.1111/ced.v47.5","key":"doi230050r18","year":"2022","issue":"5","author":"Poyner","volume":"47","first-page":"974","unstructured":null,"article-title":"Dupilumab unmasking cutaneous T-cell lymphoma: report of a fatal case.","journal-title":"Clin Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi230050r19","year":"2001","issue":"7","author":"Burg","volume":"137","first-page":"949","unstructured":null,"article-title":"From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors.","journal-title":"Arch Dermatol","doi-asserted-by":null},{"DOI":"10.1111/cup.2008.35.issue-12","key":"doi230050r20","year":"2008","issue":"12","author":"Werner","volume":"35","first-page":"1100","unstructured":null,"article-title":"Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin.","journal-title":"J Cutan Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1111/cup.2006.33.issue-s1","key":"doi230050r21","year":"2006","issue":null,"author":"Kempf","volume":"33","first-page":"58","unstructured":null,"article-title":"CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.","journal-title":"J Cutan Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1111/ajd.v64.1","key":"doi230050r22","year":"2023","issue":"1","author":"Etesami","volume":"64","first-page":"41","unstructured":null,"article-title":"Drug-induced cutaneous pseudolymphoma: A systematic review of the literature.","journal-title":"Australas J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1053/j.semdp.2017.11.003","key":"doi230050r23","year":"2018","issue":"4","author":"Magro","volume":"35","first-page":"247","unstructured":null,"article-title":"Drug induced pseudolymphoma.","journal-title":"Semin Diagn Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.v37.6","key":"doi230050r24","year":"2023","issue":"6","author":"Adam","volume":"37","first-page":"1135","unstructured":null,"article-title":"Expert consensus on the systemic treatment of atopic dermatitis in special populations.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-019-00453-7","key":"doi230050r25","year":"2019","issue":"6","author":"Vakharia","volume":"20","first-page":"771","unstructured":null,"article-title":"Adult-Onset Atopic Dermatitis: Characteristics and Management.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2005.08.057","key":"doi230050r26","year":"2005","issue":"6","author":"Pimpinelli","volume":"53","first-page":"1053","unstructured":null,"article-title":"Defining early mycosis fungoides.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi230050r13","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Public Palga Pathology Database. https://www.palga.nl/data/openbare-databank","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2023,11,1]]},"reference-count":26,"published-online":null,"references-count":26,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":35},"unpaywall":{"doi":"10.1001/jamadermatol.2023.3849","is_oa":true,"title":"Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis","updated":"2025-07-30T00:59:52+00:00","published_date":"2023-10-18","best_oa_location":{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10585590","pmh_id":"oai:pubmedcentral.nih.gov:10585590","url_for_pdf":null,"url_for_landing_page":"https://www.ncbi.nlm.nih.gov/pmc/articles/10585590"}}},"created_at":"2025-09-20T17:37:44.075Z","updated_at":"2025-09-20T18:29:21.267Z","tags":[{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"brand","value":"Dupixent","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"generic","value":"dupilumab","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"modality","value":"IL-4/IL-13 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"sample_size","value":"n=14","value_numeric":14},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"warning","value":"Molecular (TCR clonality) assessments were not consistently performed (many NA values).","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"warning","value":"The cohort only included patients on dupilumab who developed clinical suspicion for CTCL, limiting generalizability.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2023.3849","tag_type":"warning","value":"The statement of complete posttreatment clearance is based on those with available posttreatment biopsies; several patients lacked such biopsies.","value_numeric":null}],"summaries":{"what_studied":"Retrospective observational case series of adults with atopic dermatitis on dupilumab (October 2017–July 2022, single center) who developed clinical suspicion of cutaneous T‑cell lymphoma; skin biopsies before, during, and after treatment were reassessed to characterize lymphoid reactions versus mycosis fungoides.","key_result":"Among 14 patients, 3 were retrospectively diagnosed with preexisting mycosis fungoides and 11 with a dupilumab‑associated lymphoid reaction that mimicked MF clinically but showed distinctive histology (sprinkled small hyperchromatic lymphocytes in upper epidermis, dysregulated CD4:CD8 ratio, CD30 overexpression without loss of CD2/CD3/CD5); median time to clinical worsening was 4.0 months (IQR 1.4–10.0), and posttreatment biopsies showed complete clearance of the lymphoid reaction in all patients.","limitations":"Single‑center retrospective case series with a small, selected cohort limited to patients who clinically deteriorated and were suspected of CTCL; posttreatment biopsies were not available for all patients; molecular (TCR clonality) data were frequently unavailable.","practice_takeaway":"Dupilumab can trigger a benign, reversible lymphoid reaction that mimics CTCL in adults with atopic dermatitis; recognizing its distinctive histopathology and reassessing after discontinuation are key, as lesions cleared on posttreatment biopsy in this series."}}],"initialOffset":9,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Mycosis Fungoides"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Mycosis Fungoides"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Mycosis Fungoides"}}}]]

Papers